Longstreth G F, Green R
Arch Intern Med. 1983 May;143(5):902-4.
Hematologic studies, including serum and RBC folate assays, were done on 45 outpatients with chronic colitis who either took sulfasalazine (n = 27) or did not use it (n = 18). Overall, sulfasalazine users and nonusers had similar mean hemoglobin, hematocrit, serum folate, and RBC folate levels. However, within the drug users, RBC folate was inversely correlated with drug dose; serum folate was not. Patients taking 2 g or more of sulfasalazine daily had lower mean RBC folate levels (221.2 +/- 27.3 ng/mL) than patients either taking less (371.7 +/- 35.0 ng/mL) or nonusers (330.3 +/- 30.3 ng/mL). Mean corpuscular volume was also related to drug dose but not to RBC folate. Although maintenance sulfasalazine use rarely causes clinically significant folate deficiency, subclinical tissue depletion occurs as a dose-related effect.
对45例慢性结肠炎门诊患者进行了血液学研究,包括血清和红细胞叶酸检测,这些患者要么服用柳氮磺胺吡啶(n = 27),要么未使用该药(n = 18)。总体而言,柳氮磺胺吡啶使用者和未使用者的平均血红蛋白、血细胞比容、血清叶酸和红细胞叶酸水平相似。然而,在药物使用者中,红细胞叶酸与药物剂量呈负相关;血清叶酸则不然。每日服用2克或更多柳氮磺胺吡啶的患者,其平均红细胞叶酸水平(221.2±27.3纳克/毫升)低于服用量较少的患者(371.7±35.0纳克/毫升)或未使用者(330.3±30.3纳克/毫升)。平均红细胞体积也与药物剂量有关,但与红细胞叶酸无关。尽管持续使用柳氮磺胺吡啶很少导致临床上显著的叶酸缺乏,但亚临床组织耗竭会作为一种剂量相关效应而出现。